Literature DB >> 30416665

Prognostic significance of PD-L1 expression and tumor infiltrating lymphocytes in large cell neuroendocrine carcinoma of lung.

Yoichi Ohtaki1,2, Kyoichi Kaira3, Jun Atsumi1,2,4, Toshiteru Nagashima1,2,4, Osamu Kawashima4, Takashi Ibe5, Mitsuhiro Kamiyoshihara5, Ryoichi Onozato6, Atsushi Fujita6, Tomohiro Yazawa7, Masayuki Sugano7, Misaki Iijima1,2, Seshiru Nakazawa1,2, Kai Obayashi1,2, Takayuki Kosaka1,2, Toshiki Yajima1,2, Hiroyuki Kuwano2, Ken Shirabe2, Akira Mogi1,2, Kimihiro Shimizu1,2.   

Abstract

OBJECTIVES: Since large cell neuroendocrine carcinoma (LCNEC) is a relatively rare histologic type of primary lung cancer, little is known about the immunological status of patients with LCNEC. We aimed to clarify the expression and prognostic impact of programmed cell death ligand 1 (PD-L1), CD8, CD4, and Forkhead box protein P3 (Foxp3) in LCNEC.
METHODS: We retrospectively analyzed PD-L1, CD8, CD4, and Foxp3 expressions in 95 surgically resected LCNEC. PD-L1 positive staining was determined in tumors with more than 1% of tumor cells stained to any intensity, and CD8, CD4, and Foxp3 positivity was determined in tumors with more than 5% of lymphocytes stained.
RESULTS: Positive expression of PD-L1, CD8, CD4, and Foxp3 was observed in 70 (74%), 52 (55%), 76 (80%), and 43 (45%) tumors, respectively. The expression of PD-L1 was significantly correlated with positive lymphatic permeation. Positive correlations were mutually observed among tumor infiltrating immune cells. Univariate and multivariate analyses showed that positive pleural invasion and Foxp3 negative expression were independent unfavorable prognostic factors for overall survival (OS). Advanced pathological stage, positive pleural invasion, CD4 negative expression in cancer stroma, and Foxp3 negative expression were identified as independent unfavorable prognostic factors for recurrence free survival (RFS).
CONCLUSIONS: Foxp3 positive tumor infiltrating lymphocytes (TILs) were an independent favorable prognostic factor for both OS and RFS, whereas CD4 positive TILs were an independent significant unfavorable prognostic factor for RFS. The high frequency of PD-L1 expression could support the use of anti-programmed cell death 1 antibody in the treatment of LCNEC.

Entities:  

Keywords:  Foxp3; Large cell neuroendocrine carcinoma (LCNEC); PD-L1; lung cancer; tumor infiltrating lymphocyte (TIL)

Year:  2018        PMID: 30416665      PMCID: PMC6220228     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  39 in total

1.  Prognostic Role of Tumor-Infiltrating Lymphocytes in Lung Cancer: a Meta-Analysis.

Authors:  Yiting Geng; Yingjie Shao; Wenting He; Wenwei Hu; Yanjie Xu; Jun Chen; Changping Wu; Jingting Jiang
Journal:  Cell Physiol Biochem       Date:  2015-10-30

2.  LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.

Authors:  Yayi He; Hui Yu; Leslie Rozeboom; Christopher J Rivard; Kim Ellison; Rafal Dziadziuszko; Kenichi Suda; Shengxiang Ren; Chunyan Wu; Likun Hou; Caicun Zhou; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2017-01-26       Impact factor: 15.609

3.  Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer.

Authors:  Hidenobu Ishii; Koichi Azuma; Akihiko Kawahara; Kazuhiko Yamada; Yohei Imamura; Takaaki Tokito; Takashi Kinoshita; Masayoshi Kage; Tomoaki Hoshino
Journal:  J Thorac Oncol       Date:  2015-03       Impact factor: 15.609

4.  PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.

Authors:  Wendy A Cooper; Thang Tran; Ricardo E Vilain; Jason Madore; Christina I Selinger; Maija Kohonen-Corish; PoYee Yip; Bing Yu; Sandra A O'Toole; Brian C McCaughan; Jennifer H Yearley; Lisa G Horvath; Steven Kao; Michael Boyer; Richard A Scolyer
Journal:  Lung Cancer       Date:  2015-05-18       Impact factor: 5.705

5.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

6.  Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.

Authors:  K Azuma; K Ota; A Kawahara; S Hattori; E Iwama; T Harada; K Matsumoto; K Takayama; S Takamori; M Kage; T Hoshino; Y Nakanishi; I Okamoto
Journal:  Ann Oncol       Date:  2014-07-09       Impact factor: 32.976

7.  Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers.

Authors:  Takuro Saito; Hiroyoshi Nishikawa; Hisashi Wada; Yuji Nagano; Daisuke Sugiyama; Koji Atarashi; Yuka Maeda; Masahide Hamaguchi; Naganari Ohkura; Eiichi Sato; Hirotsugu Nagase; Junichi Nishimura; Hirofumi Yamamoto; Shuji Takiguchi; Takeshi Tanoue; Wataru Suda; Hidetoshi Morita; Masahira Hattori; Kenya Honda; Masaki Mori; Yuichiro Doki; Shimon Sakaguchi
Journal:  Nat Med       Date:  2016-04-25       Impact factor: 53.440

8.  Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy.

Authors:  Morena Fasano; Carminia Maria Della Corte; Federica Papaccio; Fortunato Ciardiello; Floriana Morgillo
Journal:  J Thorac Oncol       Date:  2015-08       Impact factor: 15.609

9.  Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer.

Authors:  Dong-Qiang Zeng; Yun-Fang Yu; Qi-Yun Ou; Xiao-Yin Li; Ru-Zhi Zhong; Chuan-Miao Xie; Qiu-Gen Hu
Journal:  Oncotarget       Date:  2016-03-22

10.  Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma.

Authors:  S Han; C Zhang; Q Li; J Dong; Y Liu; Y Huang; T Jiang; A Wu
Journal:  Br J Cancer       Date:  2014-04-01       Impact factor: 7.640

View more
  11 in total

1.  Genomic Profiling and Clinicopathological Characteristics of Neuroendocrine Tumors of the Lung in East Asian Patients.

Authors:  Moonsik Kim; Yeon Seung Chung; Kyoung A Kim; Hyo Sup Shim
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

Review 2.  Lung neuroendocrine tumors: A systematic literature review (Review).

Authors:  Cornel Savu; Alexandru Melinte; Camelia Diaconu; Ovidiu Stiru; Florentina Gherghiceanu; Ștefan Dragoș Octavian Tudorica; Oana Clementina Dumitrașcu; Angelica Bratu; Irina Balescu; Nicolae Bacalbasa
Journal:  Exp Ther Med       Date:  2021-12-28       Impact factor: 2.447

Review 3.  Survival outcomes of surgery in patients with pulmonary large-cell neuroendocrine carcinoma: a retrospective single-institution analysis and literature review.

Authors:  Yeye Chen; Jiaqi Zhang; Cheng Huang; Zhenhuan Tian; Xiaoyun Zhou; Chao Guo; Hongsheng Liu; Shanqing Li
Journal:  Orphanet J Rare Dis       Date:  2021-02-12       Impact factor: 4.123

4.  Prognostic impact of peripheral blood neutrophil to lymphocyte ratio in advanced-stage pulmonary large cell neuroendocrine carcinoma and its association with the immune-related tumour microenvironment.

Authors:  Masayuki Shirasawa; Tatsuya Yoshida; Hidehito Horinouchi; Shigehisa Kitano; Sayaka Arakawa; Yuji Matsumoto; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Shintaro Kanda; Reiko Watanabe; Noboru Yamamoto; Shun-Ichi Watanabe; Yuichiro Ohe; Noriko Motoi
Journal:  Br J Cancer       Date:  2020-11-30       Impact factor: 7.640

Review 5.  Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities.

Authors:  Miriam Grazia Ferrara; Alessio Stefani; Michele Simbolo; Sara Pilotto; Maurizio Martini; Filippo Lococo; Emanuele Vita; Marco Chiappetta; Alessandra Cancellieri; Ettore D'Argento; Rocco Trisolini; Guido Rindi; Aldo Scarpa; Stefano Margaritora; Michele Milella; Giampaolo Tortora; Emilio Bria
Journal:  Front Oncol       Date:  2021-04-15       Impact factor: 6.244

Review 6.  Management of Large Cell Neuroendocrine Carcinoma.

Authors:  Virginia Corbett; Susanne Arnold; Lowell Anthony; Aman Chauhan
Journal:  Front Oncol       Date:  2021-08-27       Impact factor: 6.244

Review 7.  Effect of Adjuvant and Palliative Chemotherapy in Large Cell Neuroendocrine Carcinoma of the Lung: A Systematic Review and Meta-Analysis.

Authors:  Hao Chen; Masashi Ishihara; Nobuyuki Horita; Hiroki Kazahari; Ryusuke Ochiai; Shigeru Tanzawa; Takeshi Honda; Yasuko Ichikawa; Kiyotaka Watanabe; Nobuhiko Seki
Journal:  Cancers (Basel)       Date:  2021-11-26       Impact factor: 6.639

8.  Comprehensive expressional analysis of chemosensitivity-related markers in large cell neuroendocrine carcinoma of the lung.

Authors:  Yoichi Ohtaki; Kyoichi Kaira; Toshiki Yajima; Bilguun Erkhem-Ochir; Osamu Kawashima; Mitsuhiro Kamiyoshihara; Hitoshi Igai; Ryoichi Onozato; Takashi Ibe; Takayuki Kosaka; Seshiru Nakazawa; Toshiteru Nagashima; Tetsunari Oyama; Ken Shirabe
Journal:  Thorac Cancer       Date:  2021-08-28       Impact factor: 3.500

Review 9.  Diagnosis and Molecular Profiles of Large Cell Neuroendocrine Carcinoma With Potential Targets for Therapy.

Authors:  Helmut Popper; Luka Brcic
Journal:  Front Oncol       Date:  2021-07-07       Impact factor: 6.244

10.  Prognostic value of the common tumour-infiltrating lymphocyte subtypes for patients with non-small cell lung cancer: A meta-analysis.

Authors:  Benchao Chen; Heng Li; Chao Liu; Xudong Xiang; Shuting Wang; Anhao Wu; Yan Shen; Gaofeng Li
Journal:  PLoS One       Date:  2020-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.